Form 4: National Healthcare Corp COO Acquires Shares and Options
SEC Form 4 Filing
Robert Michael Ussery, President and COO of National Healthcare Corp, reports acquisition of common stock and stock options.
Summary
- Robert Michael Ussery, the President and COO of National Healthcare Corp (NHC), filed a Form 4 with the SEC.
- The filing reports the acquisition of 2,563 shares of common stock and 13,500 stock options on March 5, 2024.
- The shares were granted as restricted shares subject to a three-year vesting schedule.
- The stock options, granted under the 2020 Omnibus Equity Incentive Plan, have an exercise price of $94.10 and vest ratably over three years, starting March 5, 2025.
- Ussery directly owns 153,109 shares of common stock with his spouse.
- Ussery also holds options to purchase 4,234 shares at $63.96 (expiring 02/18/2027) and 13,500 shares at $53.94 (expiring 03/08/2028).
Sentiment
Score: 6
Explanation: The sentiment is neutral to slightly positive. The acquisition of shares and options by a key executive is generally a positive sign, but the filing itself is a routine event.
Positives
- The acquisition of shares and options by a key executive could be interpreted as a positive signal about the executive's confidence in the company's future prospects.
Industry Context
Insider transactions are closely watched by investors as they can provide insights into management's perspective on the company's valuation and future performance. The acquisition of shares and options by the COO could be seen as a positive signal, especially in the healthcare industry where long-term growth prospects are often tied to regulatory changes and demographic trends.
Comparison to Industry Standards
- Comparing Ussery's holdings and recent transactions to those of executives at similar healthcare companies like Brookdale Senior Living (BKD) or LifePoint Health (LPNT) could provide a benchmark for assessing the significance of these transactions.
- Analyzing the vesting schedules and exercise prices of stock options granted to executives at these comparable companies can offer insights into industry standards for executive compensation.
Stakeholder Impact
- The reported transactions may have a minor positive impact on shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 02/18/2023 | Date of previous option grant with an exercise price of $63.96 and an expiration date of 02/18/2027. |
| 03/05/2024 | Date of the reported transactions: acquisition of common stock and stock options. |
| 03/07/2024 | Date of the Form 4 filing. |
| 03/08/2024 | Date of previous option grant with an exercise price of $53.94 and an expiration date of 03/08/2028. |
| 03/05/2025 | First vesting date (1/3) for the newly granted stock options. |
| 01/01/2025 | First vesting date (33 1/3%) for the restricted shares. |
| 03/05/2026 | Second vesting date (1/3) for the newly granted stock options. |
| 01/01/2026 | Second vesting date (33 1/3%) for the restricted shares. |
| 03/05/2027 | Final vesting date (1/3) for the newly granted stock options. |
| 01/01/2027 | Final vesting date (33 1/3%) for the restricted shares. |
| 02/18/2027 | Expiration date for options to purchase 4,234 shares at $63.96. |
| 03/08/2028 | Expiration date for options to purchase 13,500 shares at $53.94. |
| 03/05/2029 | Expiration date for the newly granted stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.